TUCSON, Ariz.--(BUSINESS WIRE)--Nuvox Pharma announces that the FDA has allowed an Investigational New

Drug (IND) application to initiate a Phase II clinical trial for its

oxygen therapeutic, NVX-108, in patients with the hypoxic solid brain

tumor, glioblastoma multiforme (GBM). NVX-108 is an injectable drug that

travels through the bloodstream arriving first at the lungs to pick up

oxygen and finally to hypoxic tissue where it passively delivers the

oxygen. It is designed to reduce tumor hypoxia in order to make tumors

more sensitive to radiation therapy and chemotherapy.

The clinical trial’s principal investigator, Baldassarre Stea, MD, PhD,

said, “Tumor hypoxia is known to be a problem in many tumor types,

including GBM. Hypoxic tumors are resistant to radiation therapy and

certain kinds of chemotherapy. By increasing tumor oxygen levels,

NVX-108 is designed to improve the effectiveness of these therapies in

order to kill cancer cells more effectively and increase patient

survival. Clinical trials are needed to see if NVX-108 can become

approved by regulators.”

NuvOx Pharma is a clinical stage pharmaceutical company that is

developing a platform of oxygen therapeutics. In addition to the above

oncology trial, the company also has a product in a Phase Ib/II clinical

trial in acute ischemic stroke, and has an IND allowed for a Phase Ib

clinical trial for sickle cell crisis. For further information, please

or contact John McGonigle at jmcgonigle@nuvoxpharma.com.

Disclaimer: Certain statements in this release may constitute

“forward-looking statements.” Actual events or results may differ

substantially as a result of risks and uncertainties facing us. The

forward-looking statements are based on current expectations as of the

date of these statements. We undertake no obligation to publicly update

or revise any forward-looking statements, whether as a result of future

events, new information, or otherwise.


NuvOx Pharma

John McGonigle